RT Journal Article
SR Electronic
T1 Survival after somatostatin-based radiopeptide therapy with [<sup>90</sup>Y-DOTA]-TOC and [<sup>90</sup>Y-DOTA]-TOC plus [<sup>177</sup>Lu-DOTA]-TOC in metastasized gastrinoma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 196
OP 196
VO 54
IS supplement 2
A1 Dumont, Rebecca
A1 Seiler, Daniela
A1 Marincek, Nicolas
A1 Rochlitz, Christoph
A1 Mueller-Brand, Jan
A1 Maecke, Helmut
A1 Briel, Matthias
A1 Walter, Martin
YR 2013
UL http://jnm.snmjournals.org/content/54/supplement_2/196.abstract
AB 196 Objectives We aimed to explore the efficacy of [90Y-DOTA]-TOC and [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC for the treatment of metastasized gastrinoma. Methods Patients with metastasized gastrinoma were treated with repeated cycles of [90Y-DOTA]-TOC or with cycles alternating between [90Y-DOTA]-TOC and [177Lu-DOTA]-TOC until tumor progression or permanent toxicity. Multivariable Cox regression analyses were used to study predictors of survival. Results A total of 36 patients were enrolled; 30 patients received [90Y-DOTA]-TOC (median activity) and 6 patients received [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC. All patients displayed tumor uptake higher than the liver uptake. Response was found in 26 patients (72.2%), including morphological (n=12, 33.3%), biochemical (n=14, 38.9%) and/or clinical response (n=6, 16.2%). A total of 21 patients (58.3%) experienced hematotoxicity grade 1/2, while 1 patient (2.8%) experienced hematotoxicity grade 3; no grade 4 hematotoxicity occurred. Furthermore, 2 patients (5.6%) developed grade 4 renal toxicity; no grade 5 renal toxicity occurred. Responders had a significantly longer survival from time of enrollment (45.1 months, range: 37.1-53.1 months vs. 12.6 months, range: 11.0-14.2, hazard ratio: 0.20 (0.05-0.81), p=0.02). Furthermore, there was a trend towards longer survival under [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC as compared to [90Y-DOTA]-TOC alone (60.2 months, range: 19.8-100.6 months vs. 27.0 months, range: 4.0-50.0, hazard ratio: 0.21 (0.01-3.98), p=0.30). Conclusions [90Y-DOTA]-TOC and [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC are promising tools for the treatment of metastasized gastrinoma.